Irish drugmakers slash prices of older Rx medicines by 40%, which could mean saving Irish patients up to 500 euros a year

3 February 2010

With effect from February 1, the cost of long-established prescription medicines in Ireland has been reduced by 40%, the Irish Pharmaceutical Healthcare Association (IPHA) announced, which could save the nation's patients as much as 500 euros ($695) a year.

The IPHA, which represents the international research-based pharmaceutical industry, has set up a special web site on which patients can check to see if their medicines are listed, and the price reduction. This carries a detailed list of all the medicines and their new, lower prices and includes some of the most commonly prescribed medicines in the country.

Commenting on the initiative, Brian Murphy, IPHA's director of commercial affairs, said: 'We would urge patients to check the web site as those who have to pay for their medicines could save 3 euros-4 euros on every 10 euros they spend. That's a potential saving of up to 500 euros per year.'

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical